Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor.

Trial Profile

Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Perifosine (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 18 Jun 2012 Data from this trial has been published in the June 2012 issue of Cancer, according to an AEterna Zentaris media release.
    • 16 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 16 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top